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Background 
 
HPV, Cervical Cancer, and sub-Saharan Africa   
The Human Papilloma Virus (HPV) is a one of the most commonly sexually transmitted 
infections in the world (Awolude, Morhason-Bello, Denny, & Adewole, 2013; CDC, 2014). The 
virus is transmitted primarily through vaginal and anal intercourse and can also be transmitted 
via oral sex (CDC, n.d. a.). Not all infections however, cause disease; most people who are 
infected with the virus exhibit no symptoms (CDC, 2014). In fact, in many cases, HPV infection 
is self-resolving (Awolude et al., 2013). However, persistent infection with HPV is associated 
with a variety of diseases including genital warts and head and neck cancers (CDC, 2014; Cutts 
et al., 2007). Perhaps the most pressing disease contribution from HPV is its role in preventable 
cervical cancer incidence and mortality. HPV is responsible for almost all cases of cervical 
cancer in the world (WHO, n.d. a). Cervical cancer is the fourth most common cancer of women 
worldwide, affecting more than 500,000 women annually (Bruni et al., 2015). 
Like so many other diseases, there exists a stark disparity in cervical cancer incidence 
and mortality. Cervical cancer mortality disproportionately impacts countries in sub-Saharan 
Africa (Awolude et al., 2013; El-Khatib, Tota, & Kaufmann, 2012). Over 270,000 women die 
from cervical cancer annually (LaMontagne et al., 2011) and well over 85% of the cervical 
cancer mortality burden lies in sub-Saharan Africa (WHO, n.d. a.). There are over 40 different 
strains of the virus (CDC, 2014) and while all of these strains can cause infection, there are high 
risk strains are more carcinogenic than others. These include strains 16 and 18, which cause 
nearly 70% of cervical cancers and exhibit high prevalence in Africa in particular (Awolude et 
al., 2013; Bruni et al., 2015; Cutts et al., 2007). HIV/AIDS also adds a significant layer of 
complexity to HPV infection. HIV and other immune-compromising diseases contribute to 
higher levels of HPV infection as those with immunosuppressant diseases are more susceptible 
to HPV infection (Awolude et al., 2013; Cutts et al., 2007; Sankaranarayanan et al., 2013).  
The cervical cancer disparity is further exacerbated by the lack of proper screening and 
oncologic infrastructure in developing countries for early detection and treatment of the disease 
(Sankaranarayanan et al., 2013). Traditionally, pap smears are a widely useful secondary 
prevention method for the early detection of cellular changes in the cervix and possible cervical 
abnormalities ("Tests and Procedures: Pap smear," n.d. ). However, this methodology of 
screening, requiring a laboratory, is often either unavailable or unfeasible in developing countries 
due to the lack of sustainable infrastructure for cytological screening (Sankaranarayanan et al., 
2013). Methods for screening in resource-limited settings have been developed as an alternative 
to Pap Smear testing. Visual inspection of cervical cells using acetic acid have shown success in 
detecting cervical abnormalities in the absence of laboratory testing of cervical cells 
(Sankaranarayanan et al., 2013). However, both of these methods stop short of preventing 
cervical cancer infection outright.  
The introduction the HPV vaccine presents the potential for significant global impact in 
the fight against cervical cancer and a necessary preventative strategy for women and girls 
around the world especially in light of limited screening and cancer treatment facilities.  
 
Primary Prevention – The HPV Vaccine 
 There are three vaccinations against HPV currently on the market. Two have have 
subsequently received licensures for distribution in various countries around the world (Eisele & 
Munshi, 2013; Monie, Hung, Roden, & Wu, 2008). The Gardasil vaccine; which protects against 
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HPV types 6, 11, 16, 18; was created by Merck and received FDA approval in 2006; and 
Cervarix, which protects against HPV types 16 and 18, was created by GlaxoSmithKline and 
received FDA approval in 2009 (Cutts et al., 2007; FDA, 2006, 2009). The vaccines are both 
highly 95% efficacious in protecting against HPV infection (Cutts et al., 2007). The Gardasil 
vaccine is approved for use on both men and women ages 9-26, while Cervarix has been 
approved for use on women ages 9-25 (FDA, 2006, 2009). Although the vaccine 
recommendations extend until the mid-20s, the vaccine is not as effective for people who have 
not already had a prior HPV infection. For this reason, vaccination efforts are targeted to 
adolescents ages 9-13 to initiate and complete vaccination before sexual debut (CDC b., n.d.). In 
most developing countries, the focus is still on vaccinating girls (WHO b., n.d). This in part due 
to the high cost of the vaccine. An average dose of the Gardasil costs $100, meaning a full 
course of the vaccination, three injections, would cost $300 (Cutts et al., 2007). This represents a 
significant financial barrier for resource limited countries that wish to protect their women via 
vaccination.  
Recent assistance from the Global Alliance for Vaccines and Immunizations (GAVI) has 
been instrumental in providing access to the HPV vaccine for sub-Saharan Africa countries 
(GAVI, 2013). Through the work of GAVI, countries are able to purchase the HPV vaccination 
from manufacturers for $4.50 a dose (GAVI, 2013). GAVI vaccine demonstrations focus their 
preventative efforts on girls aged 9-13. As per WHO recommendations, it is most cost effective 
to focus vaccination on this population of girls (A. Sidibe, personal communication, February 4, 
2016). GAVI vaccine demonstrations have begun in several sub-Saharan Africa countries 
including Ghana and Senegal. Senegal and Ghana both have high rates of cervical cancer 
incidence and mortality, Senegal having the second highest age standardized incidence rates, 
followed by Ghana with the 4th highest (Bruni et al., 2015) making the need for cervical cancer 
interventions and prevention strategies urgent in these two settings. As the vaccine delivery 
strategies proceed with the assistance of GAVI, it is now more important than ever to educate 
about HPV, the cervical cancer connection, and the vaccine. Even further, an investigation into 
the gaps in knowledge, receptivity, and intention to vaccinate are also important to understand 
the potential challenges associated with vaccine introduction and delivery to combat challenges 
that may impede success of the program.  
Purpose 
It is important to assess the receptivity and acceptability to the HPV vaccine in order to 
discuss what challenges may lie ahead. It is particularly pertinent to understand the opinions of a 
wide variety of stakeholders. Research to date has focused on the acceptability and knowledge of 
HPV vaccine and cervical cancer in several key stakeholders such as parents (DiAngi, Panozzo, 
Ramogola-Masire, Steenhoff, & Brewer, 2011; Wamai et al., 2012), adolescents (Binagwaho et 
al., 2012), health care workers (McCarey et al., 2011; Morhason-Bello et al., 2009), and teachers 
(Remes et al., 2012). Very limited published research is available regarding HPV, the HPV 
vaccine and cervical cancer knowledge and acceptability in West Africa, specifically (Perlman et 
al., 2014). The research resulting from this study will contribute to the literature on HPV and the 
vaccine in West Africa, with a specific focus on Senegal and Ghana. As the Human 
Papillomavirus is also and STI, understanding the context of sexual and reproductive health 
(SRH) access, knowledge, and services in sub-Saharan Africa is also important in efforts to 
promote the HPV vaccine.  
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This study is comprised of two components both of which will function together to meet 
the overall goal of this study which is understanding and assessing factors influencing vaccine 
receptivity for adolescents and young adults in sub-Saharan Africa. 
 
Aims  
• Investigate factors influencing the receptivity of adolescents and young adults in 
Senegal  
• Investigate the SRH knowledge and family planning influencers, perceptions, and 
preferences among women, men, and key stakeholders in Ghana   
 
This study is also comprised of two additional standalone deliverables. The first, is a 
publishable manuscript on HPV vaccine receptivity among adolescents and young adults in 
Senegal. The second deliverable utilizes the data analysis of Senegal and Ghana to inform a data 
brief for the Kintampo Health Research Center in Brong Ahafo, Ghana to inform future HPV 
awareness and receptivity challenges (see Appendix A).  
Guiding Theory 
The research proposed for this study, in keeping with the current literature on HPV 
vaccine acceptability (Ayissi et al., 2012; Coleman, Levison, & Sangi-Haghpeykar, 2011; 
DiAngi et al., 2011; Poole et al., 2013) is based on the principles of the Health Belief Model 
(HBM; Rosenstock, 1974). The HBM posits that decisions to undertake desired health behaviors, 
here receiving the HPV vaccine, are a combination of an individual’s belief that they are at risk 
of illness (perceived susceptibility) and how serious they believe that health threat to be 
(perceived severity). Both perceived susceptibility and perceived severity are influenced by 
individual and environmental modifying factors that further influence an individual’s perception 
of these two constructs (Earp & Ennett, 1991). An individual’s perceived severity can also be 
influenced by cues to action that are meant to encourage or serve as reminders to participate in 
the desired health behavior (Glanz, Rimer, & Viswanath, 2008). The HBM also states that 
decisions to engage in the health behavior are also shaped by weighing the potential benefits 
(perceived benefits) against the costs engaging in the desired health behavior (perceived 
barriers). The construct of self-efficacy was added to the original HBM in order to account for a 
person’s belief in their abilities to be able to complete the desired action (Glanz, Rimer, & 
Viswanath, 2008; "The Health Belief Model," n.d.).  
Figure 1 (pg. 6), is a conceptual model depicting the constructs of the HBM specific to 
vaccine acceptance in sub-Saharan Africa. The conceptual model is read from left to right. The 
arrows indicate which concepts influence each other and can be either uni- or bi-directional. The 
Health Belief Model will guide the analysis of the Senegal component of this study.  
Senegal 
Methods 
The Senegal portion of this study drew from secondary data collected by the UCLA 
Fielding School of Public Health, Réseau Africain pour l’Education à la Santé, and Centre 
Régional de formation et de Recherche en Santé de la Reproduction in Senegal, West Africa. 
2,286 adolescents and young adults ages 14-22 were surveyed using a quantitative survey 
instrument in French about their general health; health information seeking avenues; and their 
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HPV and HPV vaccine knowledge and awareness. Surveys were administered at thirteen schools 
in five cities and towns in Senegal: Thiés, Fatick, Dakar, Mbour, and Ziguinchor.  
 
Figure 1: Conceptual Model of HPV Vaccine Acceptance in West Africa based on 
the Health Belief Model 
 
Outcome Variables  
There were four main outcomes of interest in this study. HPV awareness was assessed in 
the study population by asking 1) Have you ever heard of HPV? Among the HPV aware 
subsample, students were asked 2) Do you think that HPV can be contracted through sexual 
contact? This outcome was used as a measure of the respondent’s perceived susceptibility to 
possible infection with HPV. Additionally, respondents were asked about the perceived severity 
associated with HPV infection, 3) Do you think that HPV can cause cervical cancer? Finally, 
students were asked to indicate their willingness to vaccinate, the main behavioral outcome of 
the study: 4) A vaccine that protects against HPV, a virus that can cause cervical cancer, was 
recently recommended for boys and girls. Would you get the vaccine? For each of the outcomes 
in this study, students could indicate, Yes, No, or I don’t know. All four outcomes were analyzed 
using multinomial logistic regression and then were dichotomized for a multivariable logistic 
regression. The multivariable logistic regression collapsed No and I don’t know into one 
uncertainty variable, No or I don’t know. Multinomial and multivariable logistic regressions both 
produced similar results and therefore, further analysis proceeded with multivariable logistic 
regression. This study hypothesized that respondents who were aware the HPV was an STI and 
also that it could lead to cervical cancer would be more willing to receive the HPV vaccination 
than those who were not aware of the associations of HPV infection.  
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Predictor Variables 
The sample were assessed for demographic characteristics including: age, area in which 
respondents spent the majority of their lives (suburban, urban, and rural), gender, religion, 
father’s education, socioeconomic status (SES), self-rated health, number of doctor’s visits 
within the last twelve months, whether or not a health professional spoke to the student regarding 
the HPV vaccine, and for the HPV aware sub-sample, the source of their HPV knowledge. 
Students were also asked to report their sources of SRH information and their barriers to 
accessing SRH. Three of the outcome variables, knowledge that HPV is sexually transmitted, 
knowledge that it causes cervical cancer, and willingness to receive the HPV vaccine also served 
as predictors in the three models which investigated the HPV aware subsample when they were 
not the outcome of interest.  
Students selected from a list of sources and indicated either Yes or No as to whether these 
were sources of information or barriers to access. The top five most frequently cited responses 
were utilized for further analysis. Barriers to SRH access were examined as possible barriers to 
HPV awareness and vaccine willingness. Respondents were also asked to indicate on a Likert 
scale question their level of agreement to statements regarding their personal responsibility to 
meet with a physician even if they were not ill. This variable, studied as a measurement of self-
efficacy.  
Some of the predictor variables were modified and arranged for statistical analysis. For 
the religion variable, students could indicate Muslim, Christian, Animist, Without Religion, or 
Other. A small proportion of the sample reported religions other than Muslim and Christian; 
religion was subsequently dichotomized into Muslim and Not Muslim as Muslims comprised the 
largest proportion of the sample’s religious affiliation (80%). SES was assessed in this study 
using questions adapted from the Senegal Demographic and Health Survey (Measure DHS, 
2012) regarding in home access to items such as electricity, television, radio, computer, etc. 
Responses to these questions were summed and divided into quintiles. Forty-three students 
declined to answer questions related to self-rated health and number of doctor’s visits in the past 
12 months. These missing respondents were analyzed for differences in all predictor variables 
and the four main outcome variables. There were no differences between the missing forty-three 
respondents and the remaining respondents therefore they were excluded from the sample.   
 
Statistical Analysis 
All predictor variables were analyzed for frequency data and were each examined 
utilizing Contingency table Chi-Squares for each outcome to determine if there were statistically 
significant associations between the predictors and outcome variables. Outcomes and predictors 
were further analyzed using multivariable logistic regression. All statistical analysis was 
completed with  STATA v. 14 (STATA, 2015) and significance was established at the α = 0.05 
convention.  
 
Results 
 Table 1 describes the descriptive statistics of the overall sample and the bivariate results 
of ever having heard of HPV. Overall, HPV awareness in the sample was low (26%; see Table 
1). Students of the lowest SES group reported greater awareness of HPV (32%) than students of 
higher SES groups (p < 0.01). Students whose teachers were their source of SRH information 
had lower levels of HPV awareness than those whose did not receive SRH information from 
their teachers (p < 0.05).  
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After controlling for all other variables in the multivariable logistic regression model, 
students who reported growing up in rural areas showed a 63% increase in the odds of knowing 
about HPV when compared to students who grew up in urban areas (95% CI: 1.23, 2.12). 
Students whose fathers completed higher education had a 41% increase in the odds of ever 
hearing about HPV. As SES quintile increased, HPV awareness decreased. SES group one 
showed a 25% (95% CI: 0.56, 0.99) decrease in the odds of awareness as compared to SES group 
0. SES groups 2 and 3 also showed a statistically significant decrease 32% (95% CI: 0.50, 0.93) 
and 43% (95% CI: 0.40, 0.81) in the odds of HPV awareness as compared to SES Group 0. 
Higher self-rated health and increased doctor’s visits were positively associated with HPV 
awareness; OR = 1.19 (95% CI: 1.09, 1.30) and OR = 1.07 (95% CI: 1.02, 1.12) respectively. 
 
Table 1: Bivariate and Multivariable Logistic Regression Analysis of “Have you heard of 
HPV?” 
Variable 
I don't know or has not heard of 
HPV n (%) Yes, has heard of HPV n (%) 
Ever heard of HPV  
OR (95% CI)  
Reference: No  
Ever Heard of HPV (n = 2,243) 1,658 (73.92) 585 (26.08)  
Area    
Rural  268 (69.07) 120 (30.93) 1.625 (1.24, 2.12)*** 
Father Education*   1.41 (1.04, 1.92)* 
Did Not Attend 330 (78.38) 91 (21.62)  
Primary 228 (74.03) 80 (25.97)  
Secondary 311 (74.22) 108 (25.78)  
Higher Education 468 (70.16) 199 (29.84)  
Don’t know  321 (75.00) 107 (25.00)  
SES Group**    
Group 0 333 (68.10) 156 (31.90)  
Group 1 357 (74.53) 122 (25.47) 0.745 (0.559, 0.993)* 
Group 2 319 (73.33) 116 (26.67) 0.803 (0.596, 1.0809) 
Group 3 348 (76.48) 107 (23.52) 0.681 (0.499, 0.929)* 
Group 4 301 (78.18) 84 (21.82) 0.570 (0.403, 0.807)** 
Self-Rated Health**   1.193 (1.0945, 1.299)*** 
Poor 42 (82.35) 9 (17.65)  
Fair 334 (73.89) 118 (26.11)  
Good  440 (78.71) 119 (21.29)   
Very Good 395 (74.67) 134 (25.33)  
Excellent 447 (68.56) 205 (31.44)  
Doctor’s Visits in the last 12 months   1.0683 (1.0183, 1.121)** 
None  398 (75.81) 127 (24.19)  
1 Time 381 (72.71) 143 (27.29)  
2 Times  306 (78.87) 82 (21.13)  
3 Times 202 (74.54) 69 (25.46)   
4 Times 150 (70.75) 62 (29.25)  
5-9 Times 74 (70.48) 31 (29.52)  
10 Times 72 (69.90) 31 (30.10)  
I Don’t Know 75 (65.22) 40 (34.78)  
Controlling for age, gender, religion, sources of SRH information, and barriers to accessing SRH care 
 
 Table 2 details the results of the second outcome of this study, knowledge that HPV is an 
STI (perceived susceptibility). In the HPV aware sub-sample, 34% of respondents knew that 
HPV was an STI. The highest proportion of students who knew that HPV was an STI were those 
whose fathers had no education (42%; p < 0.05). Students who had previously spoken to a 
healthcare provider about the HPV vaccine were more aware that HPV is an STI than students 
who have not spoken to a provider about the vaccine (62%; p < 0.001). Students who knew that 
HPV is an STI showed greater willingness (57%) to receive the HPV vaccine than those students 
 9 
who do not know HPV’s transmission pathway. The differences in perceived susceptibility and 
willingness to vaccinate were statistically significant (p < 0.001).  
 After controlling for all other variables, respondents who had spoken to a healthcare 
provider about the HPV vaccine showed over a threefold increase in the odds of knowing that 
HPV is and STI as compared to those students who have never spoken to a provider about the 
vaccine (95% CI: 1.89, 5.36). Knowledge of HPV’s link to cervical cancer (OR = 5.32; 95% CI: 
3.29, 8.60) and willingness to receive the HPV vaccine (OR = 2.28; 95% CI: 1.41, 3.69) were 
also highly positively associated with knowledge of HPV being an STI.  
 
Table 2: Bivariate and Multivariable Logistic Regression Analysis of “Do you think that HPV 
can be contracted sexually?”  
Variable 
No or doesn't know, that HPV 
is an STI, n (%) 
Yes, knows that HPV is an 
STI, n (%) 
Knows HPV is an STI  
OR (95% CI) 
Reference: No 
Knowledge HPV is an STI (n = 585) 387 (66.2)  198 (33.9)  
Father Education*   n/a 
Did Not Attend 53 (58.2) 38 (41.8)  
Primary 53 (66.3) 27 (33.8)  
Secondary 64 (59.3) 44 (40.7)  
Higher Education 133 (66.8) 66 (33.2)  
Don’t know  84 (78.5) 23 (21.5)  
Source of HPV Knowledge***    
Internet  21 (77.8) 6 (22.2) 0.25 (0.08, 0.79)* 
Don't Remember 136 (95.1) 7 (4.9) 0.12 (0.05, 0.29)*** 
Spoken with health care professional about HPV vaccine***   
No 342 (73.2) 125 (26.8) 3.10 (1.89, 5.36) *** 
Yes 45 (38.1) 73 (61.9)  
Knowledge HPV causes cervical cancer***   
No 328 (80.0) 82 (41.4) 5.32 (3.29, 8.60) *** 
Yes 59 (15.3) 116 (58.6)  
Would you get the HPV vaccine?***   
No or I don’t know 314 (75.5) 102 (24.5) 2.28 (1.41, 3.69) *** 
Yes 73 (43.2) 96 (56.8)  
Controlling for age, area in which respondents grew up, gender, religion, sources of SRH information, self-rated 
health, doctor’s visits in the last 12 months, and barriers to accessing SRH care 
 
 Less than a third (30%) of respondents were aware of the severity of HPV infection and 
how it may lead to cervical cancer (see Table 3). There were statistically significant differences 
in awareness of perceived severity of HPV infection and father’s education. While there was no 
clear trend, students whose father’s had not attended school showed the greatest proportion 
(42%) of knowledge about HPV leading to cervical cancer (p = 0.01). Increased doctor’s visits 
were significantly associated with increased knowledge of HPV causing cervical cancer. The 
highest percentage of students who knew of the connection (52%) were those who had visited a 
doctor more than 10 times in the past twelve months (p < 0.01). Students who were willing to 
receive the HPV vaccination were more aware (54%) of the HPV and cervical cancer than those 
who were not willing or did not know whether or not they wanted to be vaccinated (20%). The 
same trend was present for knowledge that HPV was an STI. Respondents who knew that HPV 
was an STI were more aware of the relationship between HPV and Cervical Cancer than those 
who did not know HPV was an STI (p < 0.001).  
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Table 3: Bivariate and Multivariable Logistic Regression Analysis of “Do you think that HPV 
can cause cervical cancer?” 
Variable 
No or doesn't know, that 
HPV causes cervical cancer 
Yes, knows that HPV 
causes cervical 
cancer 
Knows HPV causes 
Cervical Cancer?  
OR (95% CI) 
Reference: No 
Knowledge HPV causes Cervical Cancer (n = 
585)  410 (70.09) 175 (29.91)  
Religion   0.52 (0.27, 0.98)*** 
Not Muslim 88 (71.54) 35 (28.46)  
Muslim 322 (69.70) 140 (30.30  
Father Education*   n/a 
Did Not Attend 53 (58.24) 38 (41.76)  
Primary 59 (73.75) 21 (26.25)  
Secondary 74 (68.52) 34 (31.48)  
Higher Education 137 (68.84) 62 (31.16)  
Don’t know  87 (81.31) 20 (18.69)  
SES Group*   n/a 
Group 0 102 (65.38) 54 (34.62)  
Group 1 86 (70.49) 36 (29.51)  
Group 2 74 (63.79) 42 (36.21)  
Group 3 80 (74.77) 27 (25.23)  
Group 4 68 (80.95) 16 (19.05)  
Sources of SRH information    
TV*   n/a 
No 178 (75.11) 59 (24.89)  
Yes 232 (66.67) 116 (33.33)  
Self-Rated Health   1.30 (1.06, 1.60)* 
Poor 6 (66.67) 3 (33.33)  
Fair 88 (74.58) 30 (25.42)  
Good  85 (71.43) 34 (28.57)  
Very Good 101 (75.37) 33 (24.63)  
Excellent 130 (63.41) 75 (36.59)  
Doctor’s Visits in the last 12 months**  1.15 (1.02, 1.29)* 
None  90 (70.87) 37 (29.13)  
1 Time 102 (71.33) 41 (28.67)  
2 Times  66 (80.49) 16 (19.51)  
3 Times 50 (72.46) 19 (27.54)  
4 Times 34 (54.84) 28 (45.16)  
5-9 Times 22 (70.97) 9 (29.03)  
10 Times 15 (48.39) 16 (51.61)  
I Don’t Know 31 (77.50) 9 (22.50)  
Source of HPV Knowledge***    
Doctor or HCP 111 (58.12) 80 (41.88)   
Family or friend 35 (62.50) 21 (37.50)  
Journal/Magazine 25 (55.56) 20 (44.44)  
TV Ad 41 (78.85) 11 (21.15)  
TV News 29 (63.04) 17 (36.96)  
Internet  17 (62.96) 10 (37.04)  
Radio 15 (60.00) 10 (40.00)  
Don't Remember 137 (95.80)  6 (4.20) 0.14 (0.06, 0.38)*** 
Spoken with health care professional about HPV vaccine*** n/a 
No 347 (74.30) 120 (25.70)  
Yes 63 (53.39) 55 (46.61)  
Knowledge that HPV is an STI***   5.20 (3.21, 8.43)*** 
No or I don’t know 328 (84.75) 59 (15.25)  
Yes 82 (41.41) 116 (58.59)  
Would you get the HPV vaccine?***     2.62 (1.60, 4.27)*** 
No or I don’t know 331 (79.57) 85 (20.43)   
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Yes 79 (46.75) 90 (53.25)   
Barriers to accessing SRH care   n/a 
Cost of care*    
No 239 (73.54) 86 (26.46)  
Yes 171 (65.77) 89 (34.23)  
Controlling for age, area in which respondents grew up, gender, and self-rated health  
 
Higher self-rated health and increased doctor’s visits were again positively associated 
with knowledge of HPV causing cervical cancer; OR = 1.30 (95% CI: 1.06, 1.60) and OR = 1.15 
(95% CI: 1.02, 1.29). Respondents who knew that HPV was an STI showed a 5-fold increase in 
the odds of knowing that it also caused cervical cancer as compared to those respondents with no 
knowledge that HPV is an STI (OR = 5.20; 95% 3.21, 8.43). Willingness to vaccinate was also 
positively associated with knowledge of HPV causing cervical cancer; students who were willing 
to vaccinate showed greater than doubled the odds off knowing that HPV is linked to cervical 
cancer (OR = 2.62; 95% CI: 1.60, 4.23).  
 Table 4 describes respondents’ willingness to receive the HPV vaccine. Statistically 
significant differences existed between father’s education and willingness to vaccinate (p < 
0.001). Willingness to vaccinate was highest in respondents whose fathers had no education 
(48%). Students who received SRH information from their teachers were more willing to 
vaccinate (33%) than those who did not (24%; p < 0.05). Willingness to vaccinate was highest in 
respondents who had spoken to a healthcare provider about the HPV vaccine (p < 0.01). 
Willingness to vaccinate was highest among students who knew that HPV causes cervical cancer 
(51%; p < 0.001) and among those who knew that HPV is an STI (p < 0.001).  
 
Table 4: Bivariate and Multivariable Logistic Regression Analysis of willingness to receive the 
HPV Vaccine 
Variable 
No or doesn't know, that HPV 
causes cervical cancer, n (%) 
Yes, knows that HPV causes 
cervical cancer, n (%) 
Willingness to receive 
HPV vaccine 
OR (95%), Ref: No  
Willingness to vaccinate 416 (71.11) 169 (28.89)  
Father Education***    
Did Not Attend 47 (51.65) 44 (48.35)  
Primary 61 (76.25) 19 (23.75) 0.336 (0.155, 0.727)** 
Secondary 76 (70.37) 32 (29.63) 0.403  (0.201, 0.806)* 
Higher Education 141 (70.85) 58 (29.15) 0.414 (0.217, 0.793)** 
Don’t know  91 (85.05) 16 (14.95) 0.214 (0.0958, 0.477)*** 
Sources of SRH information   
Teachers*   n/a 
No 192 (75.89 61 (24.11)  
Yes 224 (67.47) 108 (32.53)  
Parents   0.56 (0.36, 0.88)* 
No 162 (67.50) 78 (32.50)  
Yes 254 (73.62) 91 (26.38)  
Self-Rated Health*   n/a 
Poor 9 (100.00) 0 (0.00)  
Fair 81 (68.64) 37 (31.36)  
Good  88 (73.95) 31 (26.05)  
Very Good 104 (77.61) 30 (22.39)  
Excellent 134 (65.37) 71 (34.63)  
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Table 4: Bivariate and Multivariable Logistic Regression Analysis of willingness to receive the 
HPV Vaccine (cont.) 
Variable 
No or doesn't know, that HPV 
causes cervical cancer, n (%) 
Yes, knows that HPV causes 
cervical cancer, n (%) P-value 
Source of HPV Information ***  n/a 
Doctor or HCP 124 (64.92) 67 (35.08)  
Family or friend 36 (64.29) 20 (35.71)  
Journal/Magazine 29 (64.44) 16 (35.56)  
TV Ad 35 (67.31) 17 (32.69(  
TV News 27 (58.70) 19 (41.30)  
Internet  18 (66.67) 9 (33.33)  
Radio 16 (64.00) 9 (36.00)  
Don't Remember 131 (91.61) 12 (8.39)  
Spoken with health care professional about HPV vaccine** n/a 
No 346 (74.09) 121 (25.91)  
Yes 70 (59.32) 48 (40.68)  
Barriers to accessing SRH care  n/a 
Don’t want parents to know*   
No 210 (75.27) 69 (24.73)  
Yes 206 (67.32) 100 (32.68)  
Difficulty asking SRH  questions**   
No 222 (77.62) 64 (22.38)  
Yes 194 (64.88) 105 (35.12)  
Fear of being judged**    
No 224 (75.93) 71 (24.07)  
Yes 192 (66.21) 98 (33.79)  
Don’t know where to go*   
No 257 (74.49) 88 (25.51)  
Yes 159 (66.25) 81 (33.75)  
Knowledge that HPV is an STI***  2.260  (1.406, 3.632)** 
No 314 (81.14) 73 (18.86)  
Yes 102 (51.52) 96 (48.48)  
Knowledge that HPV causes cancer***   2.773 (1.713, 4.487)*** 
No 331 (80.73) 79 (19.27)   
Yes 85 (48.57) 90 (51.43)   
Controlling for age, gender, religion, SES, and doctor’s visits in the last 12 months 
 
Table 4 also contains the multivariable logistic regression of respondents’ willingness to 
receive the HPV vaccine. After controlling for all other variables, every level of father’s 
education showed a negative association with willingness to vaccinate as compared to the 
respondents whose father’s had received no education (see table 5). Respondents who receive 
SRH information from their parents showed a 43% decrease in the odds of willingness to 
vaccinate (95% CI: 0.36, 0.88). Knowledge that HPV is an STI (perceived susceptibility) and 
that HPV infection can lead to cervical cancer (perceived severity) were positively associated 
with an increase of the odds of willingness to vaccinate. Knowledge of HPV being and STI more 
than doubled (OR = 2.26) the odds of willingness to receive the vaccine (95% CI: 1.41, 3.63). 
Similarly, knowledge that HPV was an STI was associated with more than a 2.5-fold increase 
(OR = 2.78) in the odds of being willing to vaccinate (95% CI: 1.71, 4.49).  
 
Discussion 
  The results of this study reveal an overall need to raise awareness about HPV, the 
transmission pathway, cervical cancer, and the HPV vaccine. Healthcare providers in this study 
were an important source of HPV and SRH health information. Respondents who had had more 
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opportunities throughout the year to interact with physicians were more aware of HPV and also 
showed an increase in the odds of knowing that HPV causes cervical cancer. Visits with 
physicians and other health care professionals provide an important opportunity to raise 
awareness among adolescents and young adults in Senegal. It is important to continue to use 
healthcare providers and visits as an opportunity to education and raise awareness among 
adolescents and young adults, but the results of this study reveal that information regarding HPV, 
cervical cancer, the vaccine are often segmented. Adolescents and young adults who had spoken 
to a provider about the HPV vaccine showed a statistically significant increase in the odds of 
knowing that HPV was an STI as compared to those who had not. However, the same was not 
true of knowledge of HPV leading to cervical cancer. Statistically significant increases in the 
odds of knowing HPV leads to cervical cancer were only seen in respondents with increased 
doctor’s visits. It is important for healthcare providers to educate adolescents and young adults 
about both aspects of HPV infection and cervical cancer at all points. Knowledge about the 
transmission and results of persistent infection were highly important for the end behavior of 
increasing willingness to vaccinate. 
 Perceived susceptibility to infection and perceived severity of the infection leading to 
cervical cancer mattered tremendously in this study. These two factors more than doubled the 
odds of being willing to vaccinate. These results underscore the importance of continuing to 
provide full and complete information and raising awareness of why the HPV vaccine is 
necessary. Simply by increasing awareness of these two predictors, this study showed that youth 
and adolescents could be more receptive to vaccination when they believe vaccination to be 
beneficial in protecting them from future infection and illness. Awareness and education 
campaigns should focus attention on increasing not only awareness about the availability of the 
HPV vaccine but also on ensuing that students understand the transmission of HPV and the 
benefit of avoiding cervical cancer. However, adolescents and young adults are not the only 
stakeholders in need of more information, but parents should be provided with greater access to 
information as well.  
 Parents as stakeholders to their children’s health need to be provided with more 
information to help them remain informed decision makers for their children health. Although 
students with highly educated fathers in this study were more aware of HPV, these same 
students, when compared to students whose father’s had no education, showed a reduction in the 
odds of being willing to vaccinate. Previous studies have revealed several parental concerns and 
hesitations regarding HPV vaccination namely that it may lead to future infertility, concerns over 
the side effects of the vaccine, and parents not seeing the need to vaccinate sexually inactive girls 
(Perlman, et al., 2014). Some parents also express a general a desire to simply have more 
information regarding the vaccine, HPV, and cervical cancer (A. Sidibe, personal 
communication, February 4, 2016). Education and awareness programs need to address these 
concerns upfront. Effective strategies have emphasized the safety and efficaciousness of the 
vaccine, leveraged the recommendation of the WHO, and have focused an emphasis on the 
benefit of the vaccine to prevent cervical cancer (PATH & LSHTM, 2015). Providing parents 
with accurate information will help them filter rumors and misinformation regarding the HPV 
vaccine that can also hamper vaccine receptivity (A. Sidibe, personal communication, February 
4, 2016; PATH & LSHTM, 2015). 
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Limitations 
 There are some limitations to the outlined study. The overall sample size for this study 
was small and decreased further for multivariable logistic regressions of the HPV aware sub-
sample. The smaller sample size may limit the overall generalizability of the results.  
Additionally, may of the predictor variables had multiple categories for respondents to choose 
(i.e. – barriers to accessing SRH care). This resulted in a model with several predictors and low 
r2 values for each of the models.  
 
Conclusion 
 Sub-Saharan African countries continuously face the dual challenge of battling emerging 
and infectious diseases. Today they also face the additional challenge of attending to these 
illnesses and chronic diseases as well. Cervical cancer is a growing problem in sub-Saharan 
Africa. Increased access to primary preventative services for women and girls to prevent the 
onset of HPV infection is a significant tool to promote women’s health, prolong life, and to 
decrease the global disparity in cervical cancer mortality.  
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Appendix A –HPV Vaccine Receptivity: Challenges and Best Practiced for the 
Kintampo Health Research Center 
 
Ghana 
Methods 
The Ghana component of this study similarly examined secondary data on sexual and 
reproductive health practices and preferences of Ghanaian men and women collected in a cross-
sectional study by the Kintampo Health Research Center as a part of the Kintampo Health and 
Demographic Surveillance System (KHDSS; Abubakari et al., 2015; Enuameh et al., 2015). 
Details of the data collection are described elsewhere (Enuameh et al., 2015). In total, 8,364 
respondents were surveyed under the KHDSS in the North and Southern regions of Brong Ahafo 
(Enuameh et al., 2015). Analysis of the sexual and reproductive health seeking behavior of men 
and women in Ghana was utilized to shed any light on knowledge, access, influencers, 
perceptions, and preferences among women, men, and key stakeholders. 
 
Predictor Variables 
 Data from the female sample were examined for demographics including age, area in 
which respondents were surveyed, educational attainment, religion, and SES. Further, 
frequencies for daughters in the sample were also analyzed, sourced of family planning 
information, and preferred contraceptive methods. Respondents were also asked questions about 
current contraceptive use, which types of contraceptive methods they have heard of or had ever 
used, and reasons for not currently using contraceptives.  
Awareness of contraceptive methods were recorded as either a spontaneous or prompted 
Yes or No. For analysis, spontaneous or prompted Yeses were collapsed into one affirmative Yes 
variable. Respondents could indicate Catholic, Protestant, Pentecostal/Charismatic, Muslim, 
Traditional/Spiritualist, No Religion, Other Christian, and Other Religions for their religious 
affiliation. Due to the low proportion of respondents reporting Protestant respondents, this 
selection was condensed into Other Christian and Traditional/Spiritualist was for similar reasons 
condensed into Other Religions. Respondent to this survey also indicated their source of 
contraceptive methods and contraceptive knowledge. There were numerous options for 
respondents to choose from each under the heading of Public Medical Sector, Private Medical 
Sector, or Other Source. These options were subsequently condensed into their respective 
headings for further analysis.  
 
Statistical Analysis 
All predictor variables were analyzed for frequency data. Similar survey questions for 
males and females were examined bivariate to assess practices and preferences by gender. All 
statistical analysis was completed with  STATA v. 14 (STATA, 2015). 
 
Results and Discussion - Ghana 
 The results and discussion of the secondary data analysis of the Kintampo Health 
Research Center Data are outlined in a Data Brief for KHRC below.  
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Limitations 
 This study and the prepared data brief are not without limitations. Primarily, the data for 
this portion of the study centers surrounding sexual and reproductive health and family planning 
and not on HPV, specifically. Therefore, inferences from this study are based on overarching 
sexual health with a focus on contraception rather than HPV or the HPV vaccine. However, this 
is a complementary study and given the nature of HPV infection (a sexually transmitted disease), 
it is plausible that SRH and FP information can be used to inform HPV, cervical cancer, and 
HPV vaccine related activities.  
 The data for this study were generated by two separate surveys, one for men and the other 
for women. Due to differences in sample size and questions asked in the study, cross gender 
comparisons were limited. This study instead focuses on general comparisons among women and 
among men and focuses on frequencies. Future studies should explore the statistical differences 
in responses for men and women.    
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Lessons learned from family planning programs to 
inform future HPV Vaccine education strategies 
Ruth K. Boansi, MPH; Dornsife School of Public Health, Drexel University 
 
 
Key Findings 
 
• Preventative	programs	such	
as	family	planning	(FP)	were	
generally	seen	in	a	positive	
light,	making	HPV	prevention	
plausible	in	this	population	
	
	
• Men	and	women	generally	
have	high	knowledge	of	
contraceptive	methods	and	
make	the	decision	to	utilize	
contraceptives	jointly	
	
	
• The	radio,	television,	and	
social	settings	can	be	used	to	
communicate	about	HPV,	
cervical	cancer,	and	the	HPV	
vaccine	
	
	
• Communicating	the	need	to	
vaccinate	may	face	challenges	
relating	to	fears	of	sexual	
promiscuity,	fear	of	side	
effects,	and	rumors	or	
misinformation	regarding	the	
vaccine	
 
Introduction 
 Cervical cancer is the most common cancer affecting 
women in sub-Saharan Africa1 where 85% of cervical cancer 
mortality lies2. Ghana has the 4th highest age-standardized 
incidence of cervical cancer mortality in West Africa3. 
Limited screening and treatment facilities to detect for 
abnormal cervical cells and treat cervical cancer4 make 
primary prevention efforts, preventing cervical cancer before 
it begins, more pressing. The HPV vaccine presents an 
opportunity to protect women and girls from future HPV 
infection and cervical cancer. As the vaccine becomes more 
widely available in sub-Saharan Africa5, and Ghana in 
particular, it is necessary to understand any barriers and 
facilitators to HPV awareness and vaccine receptivity.  
This data brief draws on sexual and reproductive health 
(SRH) and family planning (FP) data collected from the 
population covered by the Kintampo Health and Demographic 
Surveillance System of the Kintampo Health Research Center 
in the Brong Ahafo Region, Ghana in 2011. This brief 
examines knowledge/access to SRH and FP services as well 
as influencers/perceptions to and regarding the use of these 
services to inform any possible challenges or directions for 
future HPV awareness campaigns for the Brong Ahafo region.   
 
Demographics 
Demographic data were collected for the women surveyed:  
• Women ranged in age from 10-49, highest proportion 
of respondents were age group 15-19 (18.8%) 
• 62% of the respondents live in rural areas 
• 60% were Christian, 29% were Muslim, 11% were 
other or no religion  
• The majority of female respondents (39%) have never 
attended school  
• Socioeconomic status was varied with highest 
proportions (23%) in Less Poor or Least Poor category 
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Knowledge and Access to Family Planning and Sexual and Reproductive 
Health Methods and Services 
• Men and women are highly aware of modern and traditional forms of contraception1. 
Overall, there are high levels of awareness of the various preventative strategies available 
to them for FP.  
 
 
 
• Popular information channels for both men and women to access FP information were the 
radio (57% of men, 47% of women), television (27% of men, 26% of women), and social 
settings (23% of men, 29% of women). These channels represent avenues to increase the 
reach for HPV/HPV vaccine awareness campaigns.  
 
Influencers and Perceptions to use of Family Planning and Sexual and Reproductive 
Health Methods and Services 
• Attitudes and perceptions regarding family planning programs provide an opportunity to 
pre-identify possible challenges to an HPV education program  
• Overall, men and women have positive perceptions of FP programs. 75% of women and 
80% of men agreed that FP programs improved overall health and well-being.  
• Although men and women have positive views on FP programs for overall health, 46% of 
women and 53% of men hold the belief that use of contraceptives may make a woman 
promiscuous which may challenge overall utilization of FP services.  
• Less than half of women (45%) and men (36%) who were using contraceptives believe 
contraceptives to be primarily a woman’s responsibility 
• Women most commonly reported (73%) making decision to use contraceptives jointly 
with their partners.  
                                                
1 Cross sex comparisons cannot be made due to the difference in sample size for men and women in this study 
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• Only 18.3% of women using a current contraceptive method were informed by their 
healthcare provider about possible side effects of their contraceptive method. 
Contraceptive compliance has been hampered in the past with African men and women 
due to fear of side effects6,7 which presents an important focus when promoting the HPV 
vaccine. 
 
Recommendations 
• Several studies in sub-Saharan Africa have revealed low levels of awareness of HPV, 
cervical cancer, and the HPV vaccine8. It will be important to therefore, first increase 
overall awareness. 
• Frame messaging to focus on the benefit that the HPV vaccine provides, namely the 
prevention of cervical cancer.  
o As HPV is an STI, some might refuse the vaccine over concerns that vaccination 
will encourage early sexual debut9. There are also already concerns regarding 
promiscuity and contraceptive use, therefore HPV education messages need to be 
framed to emphasize the protection that the vaccine provides against cervical 
cancer 
• Popular media channels, the radio and the television, in addition to interpersonal 
communication (social settings) should be utilized to increase overall awareness. 
Entertainment education programs have been effective in sub-Saharan Africa and have 
helped to modify health behaviors10,11.  
o Given that men and women make their decision regarding contraceptive use 
jointly, providing entertainment education through popular channels may also 
contribute to continued dialogue about the HPV vaccine by parents and caregivers 
who are decision makers for girls eligible for vaccination 
• The data suggests that while general awareness of contraceptive methods, this 
information falls short of informing women what effects may be associated with use. This 
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presents a twofold challenge for vaccine education and delivery. First, awareness 
campaigns need to incorporate possible side effects to vaccination, which are minimal 
compared to the benefits. Secondly, addressing possible side effects during awareness 
campaigns will help to continue to ensure that parents and adolescents are informed 
stakeholders in their healthcare decisions while also giving them the information 
necessary to counter any rumors that might lead to vaccine refusal.  
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